Molecular epidemiology of paediatric invasive pneumococcal disease in Andalusia, Spain

This study aimed to assess the impact of the introduction of pneumococcal conjugate vaccine 13 (PCV13) on the molecular epidemiology of invasive pneumococcal disease (IPD) in children from Andalusia. A population-based prospective surveillance study was conducted on IPD in children aged <14 years...

Descripción completa

Detalles Bibliográficos
Autores: Felipe, Beatriz de, Obando-Pacheco, Pablo, Carazo-Gallego, Begoña, López Martín, David, Santos Pérez, Juan Luis, González Jiménez, Yolanda, Muñoz Vilches, María José, Cardelo Autero, Nerea, González Galán, Verónica, Morón, Francisco J., Cordero Varela, Juan Antonio, Torres-Sánchez, María José, Medina Claros, Antonio, Moreno-Pérez, David, Obando, Ignacio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/306805
Acceso en línea:http://hdl.handle.net/10261/306805
https://api.elsevier.com/content/abstract/scopus_id/85136993575
Access Level:acceso abierto
Palabra clave:Genotypes
Streptococcus pneumoniae
Invasive pneumococcal disease
Pneumococcal conjugate vaccine
Serotypes
Descripción
Sumario:This study aimed to assess the impact of the introduction of pneumococcal conjugate vaccine 13 (PCV13) on the molecular epidemiology of invasive pneumococcal disease (IPD) in children from Andalusia. A population-based prospective surveillance study was conducted on IPD in children aged <14 years from Andalusia (2018-2020). Pneumococcal invasive isolates collected between 2006 and 2009 in the two largest tertiary hospitals in Andalusia were used as pre-PCV13 controls for comparison of serotype/genotype distribution. Overall IPD incidence rate was 3.55 cases per 100 000 in 2018; increased non-significantly to 4.20 cases per 100 000 in 2019 and declined in 2020 to 1.69 cases per 100 000 (incidence rate ratio 2020 vs. 2019: 0.40, 95% confidence interval (CI) 0.20-0.89, P = 0.01). Proportion of IPD cases due to PCV13 serotypes in 2018-2020 was 28% (P = 0.0001 for comparison with 2006-2009). Serotypes 24F (15%) and 11A (8.3%) were the most frequently identified non-PCV13 serotypes (NVT) in 2018-2020. Penicillin- and/or ampicillin-resistant clones mostly belonged to clonal complex 156 (serotype 14-ST156 and ST2944 and serotype 11A-ST6521). The proportion of IPD cases caused by PCV13 serotypes declined significantly after the initiation of the PCV13 vaccination programme in 2016. Certain NVT, such as serotypes 24F and 11A, warrant future monitoring in IPD owing to invasive potential and/or antibiotic resistance rates.